DCB Strengthens Drug Resilience, Focuses on ADC and Nucleic Acid Drugs
Tu Hsin-che, Chairman of the Development Center for Biotechnology (DCB), stated on the 28th that Taiwan must build autonomous drug supply capabilities to counter global supply chain uncertainties. The DCB will focus on high-end biologics, ADC, nucleic acid drugs, and green manufacturing processes to strengthen domestic supply resilience and help build a 'Biotech Silicon Valley' in Taiwan.
📋 Article Processing Timeline
- 📰 Published: May 28, 2026 at 17:57
- 🔍 Collected: May 31, 2026 at 23:52 (77h 55m after Published)
- 🤖 AI Analyzed: June 2, 2026 at 00:45 (24h 52m after Collected)
Central News Agency (Taipei, 28th) Tu Hsin-che, Chairman of the Development Center for Biotechnology (DCB), stated that with rising uncertainties in the global pharmaceutical supply chain, Taiwan must establish autonomous drug supply capabilities. The DCB will focus on technology platforms such as high-end biologics, Antibody-Drug Conjugates (ADC), nucleic acid drugs, and green manufacturing processes for active pharmaceutical ingredients (APIs) to strengthen domestic drug supply resilience and assist in building an autonomous supply chain and biomedical industry cluster in Taiwan.
During a media briefing held by the DCB today, Tu pointed out that in the past, global drug supply was highly dependent on a few countries and multinational pharmaceutical companies. Any occurrence of pandemics, wars, or supply chain disruptions could impact the domestic medical system and public medication safety. Therefore, 'drug resilience' is not just an industrial issue, but a critical strategic project related to national security and public health.
He stated that Taiwan needs to gradually build autonomous development capabilities in APIs, biologics, and high-end new drug platforms, and the DCB will play a key role in the drug resilience program.
DCB CEO Lee Tsai-kun pointed out that while Taiwan has established a certain foundation in small-molecule generic drugs and manufacturing, it still needs to accelerate the establishment of autonomous technology and platform capabilities in fields such as high-end biologics, ADC drugs, and nucleic acid drugs.
He indicated that the DCB will be responsible for developing several key technologies in the future, including biocatalytic processes for green chemistry, biosimilars, bispecific antibodies, ADC, and next-generation nucleic acid drug platforms, to strengthen Taiwan's autonomous development capabilities for high-end drugs.
Regarding small-molecule drugs, Lee said the DCB is investing in API biocatalysis and green manufacturing technologies, establishing a more internationally competitive autonomous API platform through enzyme engineering, biocatalysis, and low-carbon manufacturing technologies.
In the field of biologics, the DCB is focusing on high-end biosimilars and innovative antibody drugs. ADC technology, which has received high global attention in recent years, has also become a key strategic focus for the DCB. ADC is considered the core technology for the next wave of precision cancer treatment, and the center will further strengthen its 'precision navigation ADC drug platform' to capture the global high-end cancer treatment market.
Furthermore, in the field of next-generation nucleic acid drugs, the DCB is deploying LNP (Lipid Nanoparticle) precision delivery platform technology, combining RNA drugs, gene therapy, and nucleic acid drugs to develop next-generation gene therapy solutions.
Lee pointed out that the DCB will further upgrade the functions of the 'National Biotechnology Research Park Innovation and Incubation Center' to build an important cluster for Taiwan's 'Biotech Silicon Valley,' assisting startup teams in accelerating their entry into the international market.
During a media briefing held by the DCB today, Tu pointed out that in the past, global drug supply was highly dependent on a few countries and multinational pharmaceutical companies. Any occurrence of pandemics, wars, or supply chain disruptions could impact the domestic medical system and public medication safety. Therefore, 'drug resilience' is not just an industrial issue, but a critical strategic project related to national security and public health.
He stated that Taiwan needs to gradually build autonomous development capabilities in APIs, biologics, and high-end new drug platforms, and the DCB will play a key role in the drug resilience program.
DCB CEO Lee Tsai-kun pointed out that while Taiwan has established a certain foundation in small-molecule generic drugs and manufacturing, it still needs to accelerate the establishment of autonomous technology and platform capabilities in fields such as high-end biologics, ADC drugs, and nucleic acid drugs.
He indicated that the DCB will be responsible for developing several key technologies in the future, including biocatalytic processes for green chemistry, biosimilars, bispecific antibodies, ADC, and next-generation nucleic acid drug platforms, to strengthen Taiwan's autonomous development capabilities for high-end drugs.
Regarding small-molecule drugs, Lee said the DCB is investing in API biocatalysis and green manufacturing technologies, establishing a more internationally competitive autonomous API platform through enzyme engineering, biocatalysis, and low-carbon manufacturing technologies.
In the field of biologics, the DCB is focusing on high-end biosimilars and innovative antibody drugs. ADC technology, which has received high global attention in recent years, has also become a key strategic focus for the DCB. ADC is considered the core technology for the next wave of precision cancer treatment, and the center will further strengthen its 'precision navigation ADC drug platform' to capture the global high-end cancer treatment market.
Furthermore, in the field of next-generation nucleic acid drugs, the DCB is deploying LNP (Lipid Nanoparticle) precision delivery platform technology, combining RNA drugs, gene therapy, and nucleic acid drugs to develop next-generation gene therapy solutions.
Lee pointed out that the DCB will further upgrade the functions of the 'National Biotechnology Research Park Innovation and Incubation Center' to build an important cluster for Taiwan's 'Biotech Silicon Valley,' assisting startup teams in accelerating their entry into the international market.
FAQ
What is the strategic goal of DCB?
To build a self-reliant drug supply chain and establish Taiwan as a 'Biotech Silicon Valley' by focusing on high-end biologics.